Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Merritt

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Research|December 1, 1984
Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell linesD S Groveman, E C Borden, J A Merritt, et al.
Clinical and Experimental Immunology|July 1, 1987
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferonG T Spear, D M Paulnock, R L Jordan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-mW D Quan, G E Dean, L Spears, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1984
Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humansM J Hawkins, E C Borden, J A Merritt, et al.
Cytometry|October 12, 1999
Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacyJ W Jacobberger, R M Sramkoski, D Zhang, et al.
AIDS Research and Human Retroviruses|September 1, 1991
Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patientsT W Pitts, M J Bohanon, M F Leach, et al.
The Journal of Urology|January 1, 1992
Phase 1 trial of oral bropirimine in superficial bladder cancerM F Sarosdy, D L Lamm, R D Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinomaG L Clayman, A K el-Naggar, S M Lippman, et al.
Seminars in Oncology|August 15, 1998
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacementJ A Roth, S G Swisher, J A Merritt, et al.
Cancer Gene Therapy|May 16, 2000
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53)N Yen, C G Ioannides, K Xu, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Research|December 1, 1984
Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell linesD S Groveman, E C Borden, J A Merritt, et al.
Clinical and Experimental Immunology|July 1, 1987
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferonG T Spear, D M Paulnock, R L Jordan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-mW D Quan, G E Dean, L Spears, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1984
Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humansM J Hawkins, E C Borden, J A Merritt, et al.
Cytometry|October 12, 1999
Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacyJ W Jacobberger, R M Sramkoski, D Zhang, et al.
AIDS Research and Human Retroviruses|September 1, 1991
Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patientsT W Pitts, M J Bohanon, M F Leach, et al.
The Journal of Urology|January 1, 1992
Phase 1 trial of oral bropirimine in superficial bladder cancerM F Sarosdy, D L Lamm, R D Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinomaG L Clayman, A K el-Naggar, S M Lippman, et al.
Seminars in Oncology|August 15, 1998
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacementJ A Roth, S G Swisher, J A Merritt, et al.
Cancer Gene Therapy|May 16, 2000
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53)N Yen, C G Ioannides, K Xu, et al.
Pageof 4